EntreMed (ENMD +8%) gets a pop today after announcing earlier that it has initiated a second...

|By:, SA News Editor

EntreMed (ENMD +8%) gets a pop today after announcing earlier that it has initiated a second site at Indiana University for its Phase 2 study of ENMD-2076 in triple-negative breast cancer. Initial studies, supported by a grant from the National Cancer Institute, are already underway at the University of Colorado Cancer Center.